Jim Cramer: Why Johnson & Johnson Stock Defied Healthcare's Bear Market

Healthcare Market Performance

• 📉 This year, healthcare has been the worst-performing sector in the market by a significant margin.
• 💡 Despite the overall downturn, a few healthcare stocks have emerged as impressive winners.

Johnson & Johnson's Resilience

• 📈 Johnson & Johnson (J&J) stands out as the 10th best-performing healthcare stock in the S&P 500, up 21.5% for the year as of the last close.
• ⚠️ This performance is surprising given J&J's major litigation overhang and its primary focus on pharmaceuticals, a segment the market has generally disliked.

Diversified Business Segments

• 🛠️ J&J's strength lies in its diversification beyond pharmaceuticals; its medical device business accounts for 36% of sales.
• 🚀 The medtech division, focusing on cardiovascular, orthopedic, surgery, and vision, has been a consistent growth driver, bolstered by acquisitions like AIMED and Shockwave Medical.
• 🧠 Areas like robotic surgery, neurovascular care, and digital health showcase exciting technologies within J&J's portfolio.

Pharmaceutical Business Strength

• 💊 After spinning off its over-the-counter business (Kenvue), J&J is left with a higher-growth pharmaceutical portfolio.
• 🚫 The former over-the-counter business, which included Tylenol, is no longer a concern for J&J, especially with recent controversies surrounding its use.
• 🧐 Investors often underappreciate J&J's medtech unit, viewing the company solely as a drug company, which overlooks its broader strengths.